Differences in prevalence of asthma–COPD overlap according to different criteria

Jin Hwa Song, MD\textsuperscript{a}, Chang-Hoon Lee, MD, PhD\textsuperscript{a,∗}, Deog Keom Kim, MD, PhD\textsuperscript{b,c}, HyoungKyu Yoon, MD, PhD\textsuperscript{d}, Min Kwang Byun, MD, PhD\textsuperscript{d}, Chin Kook Rhee, MD, PhD\textsuperscript{d}, Jaechun Lee, MD, PhD\textsuperscript{d}, Woo Jin Kim, MD, PhD\textsuperscript{d}, Yong Il Hwang, MD, PhD\textsuperscript{d}, Kwang Ha Yoo, MD, PhD, Ki Suck Jung, MD, PhD

Abstract
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic airway diseases. Overlap in the clinical features of these 2 diseases is observed in many cases, and thus, the concept of asthma–COPD overlap (ACO) has recently been proposed. However, the definition of ACO and the clinical significance remains to be determined.

We evaluated the prevalence and risk of acute exacerbation in ACO among Korean COPD patients as defined by modified Spanish criteria and American Thoracic Society (ATS) Roundtable criteria. The prevalence of ACO was 47.7% (66/1383) by modified Spanish criteria and 1.9% (26/1383) by ATS Roundtable criteria. ACO, regardless of criteria, did not significant affect the exacerbation risk during at least 1-year follow-up period.

Substantial discrepancies were found in the prevalence and outcome of ACO according to different diagnostic criteria, which would compromise implementation of ACO before the definition is established.

Abbreviations: \% pred = \% predicted, ACO = asthma–COPD overlap, ATS = American Thoracic Society, BDR = bronchodilator response, CAT = COPD Assessment Test, CI = confidence interval, COPD = chronic obstructive pulmonary disease, FEV\textsubscript{1} = forced expiratory volume in 1 second, FVC = forced vital capacity, HR = hazard ratio, ICS/LABA = inhaled corticosteroid/long-acting beta 2 agonist, IgE = immunoglobulin E, IRR = incidence rate ratio, KCCOSS = Korean COPD subtype study, LAMA = long-acting muscarinic antagonist, mMRC = modified medical research council dyspnea.

Keywords: acute exacerbation, asthma–COPD overlap, chronic obstructive lung disease, prevalence

1. Introduction
Recently published guidelines for asthma\textsuperscript{[1]} and chronic obstructive pulmonary disease (COPD)\textsuperscript{[2]} have introduced asthma–COPD overlap (ACO), which is a condition having clinical features of both asthma and COPD.

Typically, asthma and COPD can be easily distinguished from each other. Asthma is a chronic airway disease that typically develops in childhood and is often accompanied by allergic conditions.\textsuperscript{[3]} Patients with asthma have type 2 inflammation promoted by helper T cells and eosinophils\textsuperscript{[4]} and usually present variable and episodic symptoms.\textsuperscript{[5]} COPD is also a chronic airway disease that is related to the smoking history of an individual.\textsuperscript{[6]} Airway inflammation predominantly caused by neutrophils and type 1 T cells is observed in COPD,\textsuperscript{[7]} leading to persistent and progressive symptoms.\textsuperscript{[8]}

However, both asthma and COPD commonly occur worldwide,\textsuperscript{[9,7]} and patients with these diseases present with similar respiratory symptoms related to airway obstruction. Advanced cases of COPD often have variable airflow obstruction, whereas those of asthma may be related to persistent airflow obstruction.\textsuperscript{[10]} Thus, ACO was introduced some years ago,\textsuperscript{[9,10]} and several studies report that patients with ACO have different clinical characteristics and courses.\textsuperscript{[9,11–13]} Because treatment for ACO may be different from that for typical COPD or asthma,\textsuperscript{[14,15]} the early and appropriate diagnosis of ACO may contribute to an improvement in the clinical outcomes of patients with ACO.

However, the acceptance of this condition as a unique disease entity in clinical practice is problematic and requires further study.\textsuperscript{[8,16]} For example, issues that require investigation include the numbers of COPD patients diagnosed with ACO, and whether these patients have a clinical course and treatment reversibility distinguishable from those of patients with COPD. Most importantly, however, the definition of ACO has not been established although several diagnostic criteria exist.\textsuperscript{[17]}

Editor: Jian Liu.

The authors report no conflicts of interest.

\textsuperscript{a} Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, \textsuperscript{b} Division of Pulmonary and Critical Care Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, \textsuperscript{c} Department of Internal Medicine, Seoul National University College of Medicine, Seoul, \textsuperscript{d} Division of Pulmonology, Department of Internal Medicine, St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, \textsuperscript{e} Division of Pulmonology, Pulmonary Medicine, Jeju National University School of Medicine, Jeju, \textsuperscript{f} Division of Pulmonology, Pulmonary Medicine, Seoul National University Hospital, \textsuperscript{g} Department of Internal Medicine, Seoul National University Hospital, \textsuperscript{h} Department of Internal Medicine and Environmental Health Center, Kangwon National University, Kangwon-do, \textsuperscript{i} Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University Medical School, Goyang, \textsuperscript{j} Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

Correspondence: Chang-Hoon Lee, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-Ro Jongno-Gu, Seoul 03080, Korea (e-mail: kaurn670@gmail.com)

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2018) 97:36(e12049)
Received: 22 February 2018 / Accepted: 1 August 2018
https://doi.org/10.1097/MD.0000000000012049
Although it is expected that clinical features, prevalence, prognosis, and treatment reversibility will vary according to different diagnostic criteria,[18] little research has been conducted on this issue. Therefore, in this prospective cohort study, we investigated the prevalence and risk of exacerbation according to 2 distinct ACO diagnostic criteria: modified Spanish criteria[19] and American Thoracic Society (ATS) Roundtable criteria.[19]

2. Methods

We analyzed data from KOCOSS (Korean COPD subtype study NCT02800499), which is a prospective and observational study enrolling COPD patients from 28 hospitals in Korea.[20] All patients enrolled in KOCOSS were provided written informed consent. COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV₁) at 80% of predicted value (FVC) <0.7 in patients aged ≥40 years and with >10 pack-years of smoking history.

ACO is defined based on either the modified Spanish criteria (at least 1 major criterion or at least 2 minor criteria in COPD patients)[19] or ATS Roundtable criteria (all 3 major criteria and at least 1 minor criterion).[19] The modified Spanish criteria are as follows: major criteria: bronchodilator response (BDR) to salbutamol >400 mL and 15% and previous history of asthma; minor criteria: serum immunoglobulin E (IgE) >100 IU/mL or history of atopy, blood eosinophils >5%, and 2 separate BDR >12% and 200 mL. When the patient fulfills at least 1 major or 2 minor criteria, they are diagnosed as ACO. ATS Roundtable are as follows: major criterion: persistent airflow limitation and aged ≥40 years, smoking >10 pack-years or equivalent air pollution exposure, and documented history of asthma before 40 years of age or BDR > 400mL; minor criteria: documented history of atopy or allergic rhinitis, 2 separate BDR > 12% and 200 mL, and blood eosinophil count of ≥500/μL. We first calculated the prevalence of ACO according to these criteria. Next, the ACO and non-ACO groups were compared. Chi-square tests or Fisher’s exact tests were applied for categorical variables, and Student’s t tests or Mann–Whitney tests were used for continuous variables. Third, we investigated the risk of exacerbation in each group. Exacerbation was defined as COPD symptom aggravation requiring systemic corticosteroids, antibiotics, or hospitalization. Time to initial exacerbation was analyzed using the Cox proportional hazard model. Incidence rates were analyzed using the negative binomial regression model adjusted by covariates, including age, sex, body mass index (BMI), total symptom score for dyspnea (St. George’s Respiratory Questionnaire [SGRQ], COPD Assessment Test [CAT], and mMRC [the modified medical research council dyspnea scale]), initial FEV₁ (%), use of inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA), and use of long-acting muscarinic antagonist (LAMA). P < .05 was considered statistically significant. All statistical analyses were performed using STATA version 14.2 (StataCorp, College Station, TX).

This study was approved by the Institutional Review Board (IRB) of each hospital (Gacheon University Gil Medical Center, Gangnam Severance Hospital, Kyung Hee University Hospital at Gangdong, Sungkyunkwan University Kangbuk Samsung Hospital, Kangwon National University Hospital, Konkuk University Hospital, Konkuk University Chungju Hospital, Kyungpook National University Hospital, Gyeongsang National University Hospital, Korea University Anam Hospital, Dongguk University Gyeongju Hospital, Dong-A University Hospital, Pusan National University Hospital, The Catholic University of Korea Bucheon St. Mary’s Hospital, Soonchunhyang University Hospital Bucheon, Seoul National University Bundang Hospital, Bundang CHA Hospital, Eulji General Hospital, Seoul National University Hospital, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Samsung Medical Center, The Catholic University of Korea St. Mary’s Hospital, Asan Medical Center, The Catholic University of Korea St. Paul’s Hospital, The Catholic University of Korea St. Vincent’s Hospital, Severance Hospital, Soonchunhyang University Seoul Hospital, Ajou University Hospital, The Catholic University of Korea Yeouido St. Mary’s Hospital, Yeungnam University Medical Center, Ulsan University Hospital,wonju Severance Christian Hospital, The Catholic University of Korea Uijeongbu St. Mary’s Hospital, Ewha Womans University Mokdong Hospital, Incheon St. Mary’s Hospital, Inha University Hospital, Ilsan Paik Hospital, Chonnam National University Hospital, Chonbuk National University Hospital, Jeju National University Hospital, Soonchunhyang University Hospital Cheonan, Hallym University Gangnam Sacred Heart Hospital, Hallym University Kangdong Sacred Heart Hospital, Hallym University Dongtan Sacred Heart Hospital, Hallym University Chuncheon Sacred Heart Hospital, Hallym University Sacred Heart Hospital, Hanyang University Guri Hospital). Also, we obtained the approval of patient’s medical records from each center and maintained confidentiality.

3. Results

In total, 1383 COPD patients were included, of which 660 (47.7%) met the modified Spanish criteria and 26 (1.9%) met the ATS Roundtable criteria. Among the patients who fulfilled the ATS Roundtable criteria, age was significantly lower for ACO than for non-ACO patients (64.8 ± 1.7 vs 69.5 ± 0.2, P < .01). Furthermore, the change in FEV₁ following salbutamol treatment (BDR, %) was higher in ACO than in non-ACO patients (19.1 ± 2.9 vs 7.1 ± 0.2, P < .01). Other demographic characteristics—SGRQ, CAT, mMRC, spirometry measurements, and previous history of acute exacerbation—were similar between ACO and non-ACO groups (Table 1).

The prevalence of ACO as defined by modified Spanish criteria and ATS Roundtable criteria was 47.7% and 1.9%, respectively. Six hundred fifteen patients (46.5% among those for whom records were available) had a history of asthma but only 33 (2.4%) patients reported asthma documentation before 40 years of age (adjusted to 27 [2.0%] showing BDR > 400 mL). Because participants in the KOCOSS study underwent annual spirometry testing, there were no cases with 2 separate tests at baseline and thus no patients were classified as meeting the criterion “two separate BDR > 12% and 200 mL.” (Table 2).

Patients with ACO according to the modified Spanish criteria (adjusted hazard ratio [HR], 0.73; 95% confidence interval [CI] = 0.50–1.08; adjusted incidence rate ratio [IRR], 0.82; 95% CI = 0.55–1.23) and ATS Roundtable criteria (adjusted HR, 0.63; 95% CI = 0.19–2.10; adjusted IRR 0.46; 95% CI = 0.11–1.90) did not affect exacerbation risk (Table 3).

4. Discussion

Our study showed a substantial difference in the prevalence of ACO according to the 2 diagnostic criteria in COPD patients. The prevalence of ACO was 47.7% when the modified Spanish criteria were applied, but only 1.9% on ATS Roundtable criteria.
Table 1
Baseline characteristics of patients with and without diagnosis for asthma-chronic obstructive pulmonary disease overlap.

| Variables                              | Total (n = 1383) | Modified Spanish criteria | ATS Roundtable criteria |
|----------------------------------------|------------------|---------------------------|-------------------------|
|                                        | ACO (n = 660)    | Non-ACO (n = 476)        | P value                 |
|                                        | ACO (n = 26)     | Non-ACO (n = 1338)       | P value                 |
| Age                                    | 69.3 ± 7.6       | 69.7 ± 6.3                | 69.0 ± 0.4              | .13 | 64.8 ± 1.7 | .01 |
| Sex (male)                             | 1264 (92.7%)     | 606 (91.3%)               | 445 (93.5%)             | .29 | 26 (100%) | .25 |
| pack-year                              | 41.6 ± 26.7      | 41.3 ± 11.1               | 42.7 ± 1.3              | .42 | 39.5 ± 5.4 | .69 |
| BMI, kg/m²                              | 22.8 ± 3.4       | 22.7 ± 0.1                | 23.0 ± 0.2              | .14 | 23.1 ± 0.6 | .61 |
| FEV₁ (% pred)                          | 1.5 ± 0.5        | 1.4 ± 0.02                | 1.4 ± 0.02              | .65 | 1.5 ± 0.1 | .77 |
| FEV₁ % pred                            | 54.7 ± 17.5      | 53.9 ± 0.7                | 54.9 ± 0.8              | .35 | 52.2 ± 2.9 | .43 |
| FVC (%)                                | 3.0 ± 0.79       | 3.0 ± 0.03                | 3.1 ± 0.04              | .11 | 3.1 ± 0.2 | .91 |
| FVC % pred                             | 80.9 ± 17.7      | 80.1 ± 0.7                | 82.2 ± 0.8              | .05 | 76.6 ± 3.5 | .21 |
| FEV₁/FVC % pred                        | 61.0 ± 42.0      | 58.2 ± 1.0                | 63.4 ± 4.4              | .21 | 57.0 ± 6.6 | .81 |
| BDR %                                  | 7.3 ± 0.3        | 8.3 ± 0.4                 | 7.2 ± 0.4               | .07 | 19.1 ± 2.9 | <.01 |
| mMRC%                                  | 1.5 ± 0.9        | 1.5 ± 0.04                | 1.5 ± 0.04              | .87 | 1.3 ± 0.2 | .21 |
| SGRQ total                             | 34.9 ± 19.0      | 34.6 ± 0.8                | 35.1 ± 0.9              | .67 | 32.9 ± 4.4 | .62 |
| CAT total                              | 15.9 ± 7.9       | 15.6 ± 0.3                | 16.1 ± 4                | .32 | 16.8 ± 1.5 | .52 |
| Total exacerbation in the past year (/yr)| 2.1 ± 2.1       | 2.0 ± 0.1                 | 2.2 ± 0.2               | .42 | 1.4 ± 0.4 | .42 |
| Severe exacerbation in the past year (/yr)| 0.7 ± 1.1      | 0.8 ± 0.1                 | 0.6 ± 0.1               | .06 | 0.3 ± 0.2 | .31 |

% pred = % predicted, ACO = Asthma-chronic obstructive pulmonary disease overlap, ATS = American thoracic society, BDR = bronchodilator response, BMI = body mass index, CAT total = COPD Assessment Test total, FEV₁ = forced expiratory volume in one second, FVC = forced vital capacity, mMRC = The modified medical research council dyspnea scale, SGRQ total = St George’s Respiratory Questionnaire total.

Table 2
Patients fulfilling the modified Spanish and American thoracic society Roundtable criteria for asthma-chronic obstructive pulmonary disease overlap.

| Modified Spanish criteria                                      | Meeting criterion (n) |
|---------------------------------------------------------------|----------------------|
| Major (1) Previous history of asthma                          | 615 (46.5%)          |
| Major (2) BDR > 15% and 400 mL                                | 27 (2.0%)            |
| Minor (1) Serum IgE > 100 IU, or history of atopy             | 270 (74.0%)          |
| Minor (2) 2 separate BDR > 12% and 200 mL                     | 206 (18.4%)          |
| Minor (3) Blood eosinophils > 5%                             | 660 (47.7%)          |
| ATS Roundtable criteria                                       |                      |
| Major (1) Post-BDR FEV₁/FVC < 0.7 and age > 40 years         | 1383 (100%)          |
| Major (2) Smoking > 10 PY or air pollution > 10 PY            | 1383 (100%)          |
| Major (3) Asthma < 40 years or BDR > 400 mL in FEV₁           | 60 (4.4%)            |
| Minor (1) History of atopy or allergic rhinitis               | 165 (12.5%)          |
| Minor (2) Two separate BDR > 12% and 200 mL                   | 0                    |
| Minor (3) Blood eosinophil count > 300/mL                     | 277 (24.6%)          |
| ACO                                                           | 26 (1.9%)            |

ACO = asthma-chronic obstructive pulmonary disease overlap, ATS = American thoracic society, BDR = bronchodilator response, FEV₁ = forced expiratory volume in one second, FVC = forced vital capacity, IgE = immunoglobulin E, PY = pack-year.

Table 3
The risk of moderate-to-severe exacerbation of chronic obstructive pulmonary disease according to asthma-chronic obstructive pulmonary disease criteria.

| Time to first moderate-to-severe exacerbation                  | Crude HR (95% CI) | P value | Adjusted HR (95% CI) | P value |
|---------------------------------------------------------------|-------------------|---------|----------------------|---------|
| ACO according to modified Spanish criteria                    | 0.75 (0.54–1.03)  | .079    | 0.73 (0.50–1.08)     | .11     |
| ACO according to ATS Roundtable criteria                      | 0.49 (0.18–1.34)  | .162    | 0.63 (0.19–2.10)     | .449    |

| Incidence rate of moderate-to-severe exacerbation              | Crude IRR (95% CI) | P value | Adjusted IRR (95% CI) | P value |
|---------------------------------------------------------------|-------------------|---------|----------------------|---------|
| ACO according to modified Spanish criteria                    | 0.84 (0.57–1.24)  | .391    | 0.82 (0.55–1.23)     | .335    |
| ACO according to ATS Roundtable criteria                      | 0.43 (0.11–1.72)  | .230    | 0.46 (0.11–1.90)     | .262    |

ACO = asthma-chronic obstructive pulmonary disease overlap, ATS = American thoracic society, CI = confidence interval, HR = hazard ratio, IRR = incidence rate ratio.

* Models adjusted for age, sex, body mass index, total St. George's Respiratory Questionnaire score, initial forced expiratory volume in 1 second (%), use of inhaled corticosteroid/long-acting beta 2 agonist, and use of long-acting muscarinic antagonist.
The possibility that cheoniksi is not the specific term for asthma can be illustrated by the fact that the percentage of patients with documented asthma history before 40 years of age was relatively small, resulting in the low percentage of major ATS roundtable criteria recorded. Our results show the weakness of diagnosis based on self-reported history. In fact, the revised Global Initiative for Asthma guidelines state the importance of objective measurement of variable expiratory airflow limitation, in combination with symptoms. In addition, only a small proportion of COPD patients had bronchodilator reversibility >400 mL, which contributed to the low rate of fulfillment for the major ATS Roundtable criteria. These findings correspond to previous studies, which reported that 4.7% (39/831) of COPD patients had BDR > 15% and 400 mL and 1.17% of those with mild COPD had BDR > 15%. In fact, this cut-off value (>400 mL) used to determine the presence of asthma does not have any supporting evidence. Both modified Spanish[11] and ATS Roundtable criteria[19] define minor ACO criteria with BDR > 12%, 200 mL on 2 separate visits, but the basis for this is also unclear.

Most previous studies have shown worse outcomes in ACO patients compared with non-ACO COPD patients,[10,12,13,23] On the other hand, a CHAIN cohort study reported enhanced differences may depend on the differences in the de statistically signi

My contributions

Conceptualization: Chang-Hoon Lee, HyoungKyu Yoon, Kwang Ha Yoo.

Data curation: Jin Hwa Song, Chang-Hoon Lee.

Formal analysis: Jin Hwa Song.

Investigation: Jin Hwa Song, Chang-Hoon Lee.

Methodology: Chang-Hoon Lee.

Project administration: Kwang Ha Yoo.

Resources: Chang-Hoon Lee, Deog Keom Kim, Kwang Ha Yoo.

Supervision: Chang-Hoon Lee.

Validation: Chang-Hoon Lee.

Visualization: Jin Hwa Song, Chang-Hoon Lee.

Writing – original draft: Jin Hwa Song, Chang-Hoon Lee.

Writing – review & editing: Chang-Hoon Lee, Deog Keom Kim, HyoungKyu Yoon, Min Kwang Byun, Chin Kook Rhee, Jaechun Lee, Woo Jin Kim, Yong Il Hwang, Kwang Ha Yoo, Ki Suck Jung.

References

[1] Global Initiative for Asthma. Global strategy for asthma management and prevention 2016. Avabile at: http://ginaasthma.org. Accessed December 2016.
[2] Mavrotilles M, Soler-Cataluna JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 2014;50(suppl 1):1-6.
[3] Fabbri LM, Romagnoli M, Corbetta I, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:418-24.
[4] Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available at: http://goldcopd.org. Accessed December 2016.
[5] Saetta M, Di Stefano A, Turzato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(3 Pt 1):822-6.
[6] Halbert RJ, Imonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003;123: 1684–92.
[7] To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012;12:294.
[8] Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med 2015;373:1241–9.
[9] Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 2011;48:279-85.
[10] Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011;12:127.
[11] Cosio BG, Soriano JB, Lopez-Campos JL, et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest 2016;149:45–52.
[12] Lange P, Colak Y, Ingebrigtsen TS, et al. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen city heart study: a prospective population-based analysis. Lancet Respir Med 2016;4: 64–62.
[13] Menezes AM, Montes de Oca M, Perez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014;145:297–304.
[14] Mavrotilles M, Soler-Cataluna JJ, Calle M, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013;41:1252–6.
[15] van den Berge M, Aalbers R. The asthma-COPD overlap syndrome: how is it defined and what are its clinical implications? J Asthma Allergy 2016;9:27–35.
[16] Barnes PJ. Asthma-COPD overlap. Chest 2016;149:7–8.
[17] Barrosseguren M, Esquinas C, Miravitles M. The asthma-COPD overlap syndrome: a new entity? COPD Res Pract 2015;1:8.
[18] Sin DD. Asthma-COPD overlap syndrome: what we know and what we don’t. Tuberc Respir Dis 2017;80:11–20.
[19] Sin DD, Miravitles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 2016;48:664–73.
[20] Lee JY, Chon GR, Rhee CK, et al. Characteristics of patients with chronic obstructive pulmonary disease at the first visit to a pulmonary medical center in Korea: the Korea COPD subgroup study team cohort. J Korean Med Sci 2016;31:553–60.
[21] de Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PloS One 2013;8:e62985.
[22] Rhee CK, Yoon HK, Yoo KH, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. COPD 2014;11:163–70.
[23] Jo YS, Lee J, Yoon HI, et al. Different prevalence and clinical characteristics of asthma-chronic obstructive pulmonary disease overlap syndrome according to accepted criteria. Ann Allergy Asthma Immunol 2017;118:696–703.e691.
[24] Mannino DM. “Haeso cheoniksi” and chronic obstructive pulmonary disease in Korea. Am J Respir Crit Care Med 2005;172:795–6.
[25] Anthonisen NR, Lindgren PG, Tashkin DP, et al. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005;26:45–51.
[26] Kim DS, Kim YS, Jung KS, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005;172:842–7.